Johnson & Johnson (NYSE: JNJ) has reported E.P.S. of $1.11 for its third fiscal quarter (ending September 30) versus $1.71 for the same period a year ago — a decline of -35%. Relative to the consensus estimate of $2.20, this was a shortfall of $-1.09. For the latest four quarters through September 30, E.P.S. were $6.09 compared to $4.81 a year ago — an increase of 27%.
Recent Price Action
Johnson & Johnson (NYSE: JNJ) stock closed at $164.10 on 10/15/24 after an increase of 1.5%. Moreover, unusually high trading volume at 176% of normal accompanied the advance. The stock has risen 2.9% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, JNJ is expected to continue to be a major Value Builder.
Johnson & Johnson has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Johnson & Johnson has a neutral Power Rating of 48 but a poor Appreciation Score of 26, with the Negative Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment